Highridge Medical Successfully Sells its Bone Healing Division to Focus on Spine Solutions
Highridge Medical, a prominent player in the global medical device industry, has recently announced the completion of a significant corporate maneuver. The company, which is part of the H.I.G. Capital portfolio, has successfully divested its EBI Bone Healing Division to Avista Healthcare Partners. This strategic decision marks a pivotal shift as Highridge aims to narrow its focus on its core spinal device business. With a strong commitment to innovation, Highridge Medical intends to enhance its offerings in surgical technologies, addressing the diverse needs of spine pathology treatments.
Founded in Parsippany, New Jersey, EBI is recognized as a leading provider of non-invasive bone stimulation devices aimed at supporting spinal and orthopedic patients. Since being acquired by H.I.G. Capital during a take-private transaction in April 2024, EBI has seen substantial investments aimed at fortifying its product development capabilities, which included the introduction of new leadership to spearhead its growth.
In response to the divestiture, Glen Kashuba, the CEO of EBI, expressed pride in the accomplishments of his team. He emphasized that this new phase presents a remarkable opportunity for the company to extend its impact by delivering effective bone healing technologies to a broader patient base. He reiterated EBI's commitment to advancing patient care and supporting clinical partners in achieving life-changing outcomes for their patients.
Mike Gallagher, Managing Director at H.I.G., shared insights on the cooperative relationship they have developed with EBI. He noted that the partnership has effectively met the growing demands for EBI's product range, highlighting the team’s sector expertise and strong commercial execution track record. Gallagher expressed confidence in EBI’s future, stating that the company is well-positioned for continued success following this transaction.
This divestiture also allows Highridge Medical to channel significant resources into its primary spine business where exciting opportunities for innovation and enhanced patient outcomes abound. By refocusing on its core spine products, Highridge aims to lead the next generation of spine care, fostering advancements that improve surgical outcomes and patient satisfaction.
Financial advisory for the transaction was provided by Robert W. Baird & Co., while the legal aspects were managed by McDermott Will & Emery LLP, ensuring that all facets of the sale were professionally handled and aligned with industry standards.
Highridge Medical has made its mark as a key contributor to the medical device field, particularly through its collaboration with surgical professionals to advance spine care. The company's extensive portfolio, backed by clinical expertise, spans solutions that address complex spine issues, motion preservation, and minimally invasive surgical procedures. As Highridge Medical steps into this new chapter, it aims not only to enhance its product offerings but also to promote advancements that lead to better surgical results for patients around the globe.
About H.I.G. Capital:
H.I.G. Capital is a distinguished global alternative investment firm, boasting $70 billion in assets under management. With a strong presence not just in the United States, but also across various international locales, H.I.G. integrates operational insights into its investment approach, ensuring that companies in its portfolio receive the support they need to thrive in competitive landscapes. With more than 400 companies invested in over its years of operation, H.I.G. is recognized for its flexible, value-added investment strategies that span across equity and debt financing, making it a trusted partner for mid-market firms globally.
Founded in Parsippany, New Jersey, EBI is recognized as a leading provider of non-invasive bone stimulation devices aimed at supporting spinal and orthopedic patients. Since being acquired by H.I.G. Capital during a take-private transaction in April 2024, EBI has seen substantial investments aimed at fortifying its product development capabilities, which included the introduction of new leadership to spearhead its growth.
In response to the divestiture, Glen Kashuba, the CEO of EBI, expressed pride in the accomplishments of his team. He emphasized that this new phase presents a remarkable opportunity for the company to extend its impact by delivering effective bone healing technologies to a broader patient base. He reiterated EBI's commitment to advancing patient care and supporting clinical partners in achieving life-changing outcomes for their patients.
Mike Gallagher, Managing Director at H.I.G., shared insights on the cooperative relationship they have developed with EBI. He noted that the partnership has effectively met the growing demands for EBI's product range, highlighting the team’s sector expertise and strong commercial execution track record. Gallagher expressed confidence in EBI’s future, stating that the company is well-positioned for continued success following this transaction.
This divestiture also allows Highridge Medical to channel significant resources into its primary spine business where exciting opportunities for innovation and enhanced patient outcomes abound. By refocusing on its core spine products, Highridge aims to lead the next generation of spine care, fostering advancements that improve surgical outcomes and patient satisfaction.
Financial advisory for the transaction was provided by Robert W. Baird & Co., while the legal aspects were managed by McDermott Will & Emery LLP, ensuring that all facets of the sale were professionally handled and aligned with industry standards.
Highridge Medical has made its mark as a key contributor to the medical device field, particularly through its collaboration with surgical professionals to advance spine care. The company's extensive portfolio, backed by clinical expertise, spans solutions that address complex spine issues, motion preservation, and minimally invasive surgical procedures. As Highridge Medical steps into this new chapter, it aims not only to enhance its product offerings but also to promote advancements that lead to better surgical results for patients around the globe.
About H.I.G. Capital:
H.I.G. Capital is a distinguished global alternative investment firm, boasting $70 billion in assets under management. With a strong presence not just in the United States, but also across various international locales, H.I.G. integrates operational insights into its investment approach, ensuring that companies in its portfolio receive the support they need to thrive in competitive landscapes. With more than 400 companies invested in over its years of operation, H.I.G. is recognized for its flexible, value-added investment strategies that span across equity and debt financing, making it a trusted partner for mid-market firms globally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.